Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hepatology
•
Viral Hepatitis
In what scenarios do you defer treatment of a patient's hepatitis C if they are undergoing liver transplant evaluation?
Related Questions
How do you explain the additional risks that a transplant recipient may carry by pursuing a hepatitis C positive organ if they are negative?
What role is there for the use of ursodiol in relapsing hepatitis A for management of liver enzyme abnormalities and patient symptoms?
What kind of monitoring do you choose in patients at risk for reactivation of hepatitis B who are on immunosuppression?
All things being equal, what patient factors are you looking at in the selection of TAF or TDF in the management of hepatitis B?
Do you recommend the use of SGLT2 inhibitors to reduce the risk of liver cirrhosis in patients with Type 2 diabetes mellitus?
What are your biggest takeaways from the MASH-TAG 2025 conference?
When would you decide to pursue plasma exchange in a patient in acute liver failure due to sinusoidal obstruction syndrome?
How do you counsel patients on the use and risks of alternative medications and supplements given how prevalent and easily accessible they are to the average person?
How do you approach treatment options for patients with fibrolamellar HCC compared to "normal" HCC?
What would be the right patient profile and experience for someone who may have (operational) tolerance and how do you approach immunosuppresison management (or withdrawal) in this patient?
